Post Profile






Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin's Lymphoma

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah(tm) (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577).
read more

share

Related Posts


CAR T-Cell therapy sends multiple myeloma into lasting remission

Diseases & Conditions / Cancer : EurekAlert: Cancer

(American Society of Clinical Oncology) In an early clinical trial, 33 out of 35 (94 percent) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy -- chimeric antigen receptor (CAR) T cells ...

Roche lymphoma drug drives high remission rate, longer survival: study

Health : Reuters: Health

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment ...

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remaine...

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Health : Newswise Medical News

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment wit...

Global CAR T therapy trial shows high rates of durable remission for NHL

Health : EurekAlert: Health

(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah? (formerly known as CTL019) demonstrated long-lasting rem...

Comments


Copyright © 2016 Regator, LLC